ReviewCurrent opinion in structural biology2014
Better and faster: improvements and optimization for mammalian recombinant protein production.
Review in Current opinion in structural biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Toward the Development of a Biosimilar Variant of Glucarpidase (Carboxypeptidase G2): Secretory Production, Optimization, and Immobilization.Molecular biotechnology · 2026Article
- Effect of recombinant protein production and release on microalgal fitness and the impact of environmental conditions for localized therapeutic delivery.Journal of biological engineering · 2025Article
- The Role of Endoplasmic Reticulum Stress on Reducing Recombinant Protein Production in Mammalian Cells.Biochemical engineering journal · 2024Article
- Recombinant and Synthetic Affibodies Function Comparably for Modulating Protein Release.Cellular and molecular bioengineering · 2024Article
- Development of novel lipoplex formulation methodologies to improve large-scale transient transfection for lentiviral vector manufacture.Molecular therapy. Methods & clinical development · 2024Article
- Improved Manufacturing Methods of Extracellular Vesicles Pseudotyped with the Vesicular Stomatitis Virus Glycoprotein.Molecular biotechnology · 2024Article
- Enhancing the productivity and proliferation of CHO-K1 cells by oncoprotein YAP (Yes-associated protein).Applied microbiology and biotechnology · 2024Article
- The Use of Baculovirus-Mediated Gene Expression in Mammalian Cells for Recombinant Protein Production.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Cloning and Optimization of Intracellular Expression of Human Interferon β-1a inAdvanced biomedical research · 2024Article
- Dot-Blotting: A Quick Method for Expression Analysis of Recombinant Proteins.Current protocols · 2022Article
- The past, present, and future of enzyme-based therapies.Drug discovery today · 2022Review
- Recombinant Protein Expression and Purification of N, S1, and RBD of SARS-CoV-2 from Mammalian Cells and Their Potential Applications.Diagnostics (Basel, Switzerland) · 2021Article
- Article
- The future of self-selecting and stable fermentations.Journal of industrial microbiology & biotechnology · 2020Review
- Mammalian Expression andACS omega · 2020Article
- Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells.Protein science : a publication of the Protein Society · 2020Article
- Optimization of culture conditions for the expression of three different insoluble proteins in Escherichia coli.Scientific reports · 2019Article
- Smoothing membrane protein structure determination by initial upstream stage improvements.Applied microbiology and biotechnology · 2019Review
- The role of magnetic field in the biopharmaceutical production: Current perspectives.Biotechnology reports (Amsterdam, Netherlands) · 2019Review
- Identifying HIPK1 as Target of miR-22-3p Enhancing Recombinant Protein Production From HEK 293 Cell by Using Microarray and HTP siRNA Screen.Biotechnology journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Thanks to numerous technological advances, the production of recombinant proteins in mammalian cell lines has become an increasingly routine task that is no longer viewed as a heroic enterprise. While production in prokaryotic or lower eukaryotic systems may be more rapid and economical, the advantages of producing large amounts of protein that closely resembles the native form is often advantageous and may be essential for the realization of functionally active material for biological studies or biopharmaceuticals. The correct folding, processing and post-translational modifications conferred by expression in a mammalian cell is relevant to all classes of proteins, including cytoplasmic, secreted or integral membrane proteins. Therefore considerable efforts have focused on the development of growth media, cell lines, transformation methods and selection techniques that enable the production of grams of functional protein in weeks, rather than months. This review will focus on a plethora of methods that are broadly applicable to the high yield production of any class of protein (cytoplasmic, secreted or integral membrane) from mammalian cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.